Evaluation value of serum ANXA1 and ANXA2 in platinum-based chemotherapy resistance in patients with epithelial ovarian cancer and their relationship with prognosis
10.3969/j.issn.1673-4130.2024.23.009
- VernacularTitle:血清ANXA1、ANXA2在上皮性卵巢癌患者铂类化疗耐药中的评估价值及其与预后的关系
- Author:
Xingxing ZHANG
1
;
Bei WANG
;
Shasha BAI
Author Information
1. 邯郸市第一医院妇科,河北邯郸 056000
- Keywords:
annexin A1;
annexin A2;
epithelial ovarian cancer;
chemotherapy resistance;
prognosis
- From:
International Journal of Laboratory Medicine
2024;45(23):2862-2866,2872
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the value of serum annexin A1(ANXA1)and annexin A2(ANXA2)in the evaluation of platinum-based chemotherapy resistance in patients with epithelial ovarian cancer(EOC)and their relationship with prognosis.Methods A total of 125 EOC patients who were admitted to Handan First Hospital from June 2017 to June 2020 were selected.According to the chemotherapy efficacy,patients were di-vided into sensitive group(81 cases)and drug-resistant group(44 cases).The clinical data,serum ANXA1 and ANXA2 levels were compared between two groups.The influencing factors of platinum-based chemother-apy resistance in EOC patients were analyzed by multivariate Logistic regression model.The value of serum ANXA1 and ANXA2 in predicting platinum-based chemotherapy resistance in EOC patients were analyzed by receiver operating characteristic curve.The prognosis of EOC patients was analyzed by Kaplan-Meier survival curve.Results A total of 125 patients completed surgery+platinum-based chemotherapy,there were 81 cases in sensitive group and 44 cases in drug-resistant group.Compared with sensitive group,the proportion of FI-GO stage Ⅲ-Ⅳ,the proportion of lymph node metastasis,serum ANXA2 level in drug-resistant group were significantly increased(P＜0.05),and serum ANXA1 level was significantly decreased(P＜0.05).Elevated serum ANXA2 level and decreased serum ANXA1 level were risk factors for platinum-based chemotherapy re-sistance in EOC patients(P＜0.05).The area under the curve of serum ANXA1 and ANXA2 alone or in com-bination for predicting platinum-based chemotherapy resistance in EOC patients was 0.687(95％CI:0.405-0.973),0.763(95％CI:0.618-0.901),0.832(95％CI:0.720-0.948)respectively,and the predictive effica-cy of combined detection of serum ANXA1 and ANXA2 was better than that of single detection(P＜0.05).Kaplan-Meier survival curve showed that the 3-year overall survival rate in ANXA1 low expression group was significantly lower than that in ANXA1 high expression group(P＜0.05),and the 3-year overall survival rate in ANXA2 high expression group was significantly lower than that in ANXA2 low expression group(P＜0.05).Conclusion The decrease of serum ANXA1 level and the increase of ANXA2 level are related to plati-num-based chemotherapy resistance and poor prognosis in EOC patients,which are expected to be used as ear-ly warning indicators to predict platinum-based chemotherapy resistance.
